乌帕达西替尼治疗特应性皮炎患者的眼部不良事件:真实生活经验。

IF 4 3区 医学 Q1 DERMATOLOGY
Dermatitis Pub Date : 2023-09-01 Epub Date: 2023-01-23 DOI:10.1089/derm.2022.0063
Federica Gelato, Luca Mastorino, Pietro Quaglino, Giovanni Cavaliere, Michela Ortoncelli, Simone Ribero
{"title":"乌帕达西替尼治疗特应性皮炎患者的眼部不良事件:真实生活经验。","authors":"Federica Gelato,&nbsp;Luca Mastorino,&nbsp;Pietro Quaglino,&nbsp;Giovanni Cavaliere,&nbsp;Michela Ortoncelli,&nbsp;Simone Ribero","doi":"10.1089/derm.2022.0063","DOIUrl":null,"url":null,"abstract":"<p><p><b><i><u>Background:</u></i></b> Dupilumab, an interleukin (IL)-4 receptor-α inhibitor that blocks IL-4 and IL-13 signaling pathways, is an effective and well-tolerated therapy for moderate-to-severe atopic dermatitis (AD). However, an increased incidence of dupilumab-associated conjunctivitis has been reported in patients treated with dupilumab. In contrast, upadacitinib, a selective Janus kinase 1 inhibitor, is reported to have lower incidence of conjunctivitis than dupilumab. <b><i><u>Objective:</u></i></b> The aim of this retrospective study was to investigate ocular adverse events in adult patients with moderate-to-severe AD treated with upadacitinib after discontinuing treatment with dupilumab. <b><i><u>Methods:</u></i></b> In total, 33 patients were examined at the start of treatment with upadacitinib after discontinuation of dupilumab, then again after 4 weeks and every 12 weeks up to a maximum of 72 weeks. <b><i><u>Results:</u></i></b> Among the patients in the study, 14 had developed dupilumab-associated conjunctivitis during dupilumab treatment and had complete resolution of ocular symptoms after the switch to upadacitinib within the 1-month follow-up visit. In addition, only 1 patient treated with upadacitinib developed an episode of conjunctivitis. This condition was of mild severity and it spontaneously resolved quickly. Interestingly, this patient had no history of dupilumab-associated conjunctivitis. <b><i><u>Conclusions:</u></i></b> All patients who developed dupilumab-associated conjunctivitis experienced complete remission on upadacitinib and only 3% of the patients in our sample developed conjunctivitis after the start of treatment with upadacitinib. In light of this, upadacitinib appears to be a prudent and safe treatment option for AD patients with uncontrolled ocular symptoms associated with dupilumab therapy.</p>","PeriodicalId":11047,"journal":{"name":"Dermatitis","volume":" ","pages":"445-447"},"PeriodicalIF":4.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience.\",\"authors\":\"Federica Gelato,&nbsp;Luca Mastorino,&nbsp;Pietro Quaglino,&nbsp;Giovanni Cavaliere,&nbsp;Michela Ortoncelli,&nbsp;Simone Ribero\",\"doi\":\"10.1089/derm.2022.0063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i><u>Background:</u></i></b> Dupilumab, an interleukin (IL)-4 receptor-α inhibitor that blocks IL-4 and IL-13 signaling pathways, is an effective and well-tolerated therapy for moderate-to-severe atopic dermatitis (AD). However, an increased incidence of dupilumab-associated conjunctivitis has been reported in patients treated with dupilumab. In contrast, upadacitinib, a selective Janus kinase 1 inhibitor, is reported to have lower incidence of conjunctivitis than dupilumab. <b><i><u>Objective:</u></i></b> The aim of this retrospective study was to investigate ocular adverse events in adult patients with moderate-to-severe AD treated with upadacitinib after discontinuing treatment with dupilumab. <b><i><u>Methods:</u></i></b> In total, 33 patients were examined at the start of treatment with upadacitinib after discontinuation of dupilumab, then again after 4 weeks and every 12 weeks up to a maximum of 72 weeks. <b><i><u>Results:</u></i></b> Among the patients in the study, 14 had developed dupilumab-associated conjunctivitis during dupilumab treatment and had complete resolution of ocular symptoms after the switch to upadacitinib within the 1-month follow-up visit. In addition, only 1 patient treated with upadacitinib developed an episode of conjunctivitis. This condition was of mild severity and it spontaneously resolved quickly. Interestingly, this patient had no history of dupilumab-associated conjunctivitis. <b><i><u>Conclusions:</u></i></b> All patients who developed dupilumab-associated conjunctivitis experienced complete remission on upadacitinib and only 3% of the patients in our sample developed conjunctivitis after the start of treatment with upadacitinib. In light of this, upadacitinib appears to be a prudent and safe treatment option for AD patients with uncontrolled ocular symptoms associated with dupilumab therapy.</p>\",\"PeriodicalId\":11047,\"journal\":{\"name\":\"Dermatitis\",\"volume\":\" \",\"pages\":\"445-447\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatitis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/derm.2022.0063\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatitis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/derm.2022.0063","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 2

摘要

背景:Dupilumab是一种阻断IL-4和IL-13信号通路的白细胞介素(IL)-4受体-α抑制剂,是治疗中重度特应性皮炎(AD)的有效且耐受性良好的药物。然而,据报道,在接受杜匹单抗治疗的患者中,杜匹单抗相关结膜炎的发病率增加。相比之下,据报道,选择性Janus激酶1抑制剂upadacitinib的结膜炎发病率低于dupilumab。目的:本回顾性研究的目的是调查成年中重度AD患者在停用杜匹单抗治疗后使用乌帕替尼治疗的眼部不良事件。方法:总共有33名患者在停用杜匹单抗后开始接受乌帕替尼治疗时接受检查,然后在4周后再次进行检查,每12周检查一次,最长可达72周。结果:在研究中的患者中,有14名患者在杜匹单抗治疗期间出现了杜匹单抗相关结膜炎,在1个月的随访中改用乌帕替尼后,眼部症状完全缓解。此外,只有1名接受乌帕替尼治疗的患者出现结膜炎发作。这种情况严重程度较轻,很快就自行缓解了。有趣的是,该患者没有杜匹单抗相关结膜炎病史。结论:所有患上杜匹单抗相关结膜炎的患者在接受乌帕替尼治疗后都得到了完全缓解,在我们的样本中,只有3%的患者在开始接受乌帕替尼治疗后患上了结膜炎。有鉴于此,对于与杜匹单抗治疗相关的眼部症状不受控制的AD患者,乌帕替尼似乎是一种谨慎而安全的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience.

Background: Dupilumab, an interleukin (IL)-4 receptor-α inhibitor that blocks IL-4 and IL-13 signaling pathways, is an effective and well-tolerated therapy for moderate-to-severe atopic dermatitis (AD). However, an increased incidence of dupilumab-associated conjunctivitis has been reported in patients treated with dupilumab. In contrast, upadacitinib, a selective Janus kinase 1 inhibitor, is reported to have lower incidence of conjunctivitis than dupilumab. Objective: The aim of this retrospective study was to investigate ocular adverse events in adult patients with moderate-to-severe AD treated with upadacitinib after discontinuing treatment with dupilumab. Methods: In total, 33 patients were examined at the start of treatment with upadacitinib after discontinuation of dupilumab, then again after 4 weeks and every 12 weeks up to a maximum of 72 weeks. Results: Among the patients in the study, 14 had developed dupilumab-associated conjunctivitis during dupilumab treatment and had complete resolution of ocular symptoms after the switch to upadacitinib within the 1-month follow-up visit. In addition, only 1 patient treated with upadacitinib developed an episode of conjunctivitis. This condition was of mild severity and it spontaneously resolved quickly. Interestingly, this patient had no history of dupilumab-associated conjunctivitis. Conclusions: All patients who developed dupilumab-associated conjunctivitis experienced complete remission on upadacitinib and only 3% of the patients in our sample developed conjunctivitis after the start of treatment with upadacitinib. In light of this, upadacitinib appears to be a prudent and safe treatment option for AD patients with uncontrolled ocular symptoms associated with dupilumab therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Dermatitis
Dermatitis 医学-皮肤病学
CiteScore
5.30
自引率
11.50%
发文量
251
审稿时长
>12 weeks
期刊介绍: Dermatitis is owned by the American Contact Dermatitis Society and is the home journal of 4 other organizations, namely Societa Italiana di Dermatologica Allergologica Professionale e Ambientale, Experimental Contact Dermatitis Research Group, International Contact Dermatitis Research Group, and North American Contact Dermatitis Group. Dermatitis focuses on contact, atopic, occupational, and drug dermatitis, and welcomes manuscript submissions in these fields, with emphasis on reviews, studies, reports, and letters. Annual sections include Contact Allergen of the Year and Contact Allergen Alternatives, for which papers are chosen or invited by the respective section editor. Other sections unique to the journal are Pearls & Zebras, Product Allergen Watch, and news, features, or meeting abstracts from participating organizations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信